search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Business


Continued from page 22


10Vallianatou T et al (2018). A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability. Neuroimage, 172: 808-816. 11 Cong L et al (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121): 819-823. 12 Mali P et al (2013). RNA- guided human genome engineering via Cas9. Science, 339 (6121): 823-826. 13 Goransson, M et al (2016). SIK Inhibition: A Novel Opportunity to Modulate Disease Phenotype in COPD. ATS 2016. san Francisco: American Journal of Respiratory and Critical Care Medicine. 14 Gad, H et al (2014). MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature, 508 (7495): 215-221. 15 Huber, K et al. (2014). Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy. Nature, 508(7495): 222-227. 16 Kettle, J et al (2016). Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival. Journal of medicinal Chemistry, 59 (6): 2346-2361. 17 Canver, M et al (2018). Integrated design, execution, and analysis of arrayed and pooled CRISPR genome- editing experiments. Nature Protocols, 13: 946-986.


a way that will better inform and identify putative therapeutic targets. The 5R framework has helped refine the selec-


tion of molecules we feed into the clinical pipeline, and has led to an improvement in the quality of the drug candidates we take forward into clinical trials. Continuous review and evolu- tion of our drug discovery and development approaches will hopefully uncover further oppor- tunities for continued improvement in our pro- ductivity, and our ability to bring innovative medicines to patients faster.


DDW


Dr Lorna C. Ewart heads AstraZeneca’s Centre of Excellence for Microphyisological Systems. Here she has established strategic collaborations with leading external academics as well as led technolo- gy transfer into AstraZeneca. She is a trained phar- macologist with 20 years’ experience in the phar- maceutical industry spanning both the efficacy and safety domains.


Dr Richard J.A. Goodwin is a Principal Scientist at AstraZeneca and leads the mass spectrometry imaging group within Drug Safety and Metabolism. He joined AstraZeneca in Sweden as a post doc in 2011. Since then he has helped build the multimodal imaging capability through inter- nal expansion and external collaborations. Dr Stephen E. Fawell is Vice President, Head Oncology iScience, for the IMED Biotech Unit at AstraZeneca, with responsibility for target selec- tion, drug discovery and optimisation and oversee- ing biology, pharmacology, DMPK and chemistry resources. Steve obtained his PhD at the University of Leeds, UK, and completed post-doctoral fellow- ships at Rutgers Medical School NJ and the Imperial Cancer Research Fund.


Dr Pernille B.L. Hansen is head of Bioscience Chronic Kidney Disease of AstraZeneca’s IMED Biotech Unit, responsible for delivering new tar- gets for CKD and lead the bioscience kidney disci- pline. She holds a Professorship in Cardiovascular and Renal Research at University of Southern Denmark.


Dr Catherine C. Priestley leads Science Communications and Relations for IMED Biotech Unit at AstraZeneca and is a member of the ABPI Innovation Board where she advises on areas of focus for UK life sciences. As a toxicologist, she has published more than 30 manuscripts assessing the safety profile of new modalities.


24 Drug Discovery World Summer 2018


Steve Rees is Vice President of Discovery Biology at AstraZeneca. He is Chair of the European Laboratory Research and Innovation group (ELRIG) and is a member of the Scientific Advisory Board for LifeArc and the Centre for Membrane Protein and Receptor research at the Universities of Nottingham and Birmingham.


Dr Menelas (Mene) Pangalos is Executive Vice President of AstraZeneca’s IMED Biotech Unit and AstraZeneca’s Global Business Development. Mene has overall responsibility for AstraZeneca’s research and early development activities spanning three continents and 2,500 people. As one of AstraZeneca’s leading scientists, Mene has pub- lished more than 150 peer-reviewed articles and served as editor of numerous books and journals.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80